Acute Pyelonephritis - Pipeline Insight, 2025
Description
DelveInsight’s, “Acute Pyelonephritis - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Acute Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acute Pyelonephritis: Overview
Acute pyelonephritis is a bacterial infection that causes inflammation in the kidney parenchyma and renal pelvis. It typically develops rapidly over a few hours or a day and is often accompanied by high fever, flank pain, nausea, vomiting, and other symptoms. The infection usually ascends from the lower urinary tract but can also spread through the bloodstream. Timely diagnosis and treatment are crucial to prevent serious complications such as kidney scarring, abscess formation, sepsis, and multiorgan system failure. Acute pyelonephritis symptoms typically include fever, flank pain, chills, nausea, vomiting, and anorexia, burning on urination, increased frequency, and urgency. The most common symptoms are fever and flank pain, which can be accompanied by other symptoms such as nausea, vomiting, and abdominal pain that radiates along the flank towards the back. In some cases, symptoms may develop rapidly over a few hours or a day, while in others, they may not occur at the same time. The presentation can vary with age, with newborns often showing poor feeding and vomiting, and children under 2 years old experiencing fever, poor appetite, and vomiting.
It is diagnosed primarily through a combination of clinical evaluation, urinalysis, and laboratory tests. The diagnosis is often suggested by the patient's history and physical examination, which typically includes symptoms such as fever, costovertebral angle pain, nausea, vomiting, and flank pain. Urinalysis is crucial, as it can reveal signs of pyuria, hematuria, or leukocytosis. Laboratory tests, such as blood cultures and peripheral blood smears, may also be ordered to confirm the diagnosis. Imaging studies, such as ultrasound or CT scans, are usually reserved for cases where the presentation is atypical or the patient does not respond to therapy, as they can help identify complications like nephrolithiasis, obstructive uropathy, or perinephric abscess.
Acute pyelonephritis is typically treated with antibiotics, with the choice of antibiotic depending on the identified bacteria. For uncomplicated cases in young, healthy women, a single dose of a parenteral antibiotic followed by oral therapy is effective. For more severe cases or those in high-risk groups (e.g., elderly, pregnant, or immunocompromised), hospitalization with intravenous antibiotics is recommended. Outpatient therapy is also successful in 90% of selected patients with uncomplicated acute pyelonephritis who can tolerate oral intake, are compliant with the treatment regimen, and have adequate social support. The duration of treatment varies, with 14 days being the standard for most cases, but 7 days being sufficient for young, healthy women receiving fluoroquinolones
""Acute Pyelonephritis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pyelonephritis pipeline landscape is provided which includes the disease overview and Acute Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Acute Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Acute Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Pyelonephritis Emerging Drugs
NRX-101: NeuroRx
NRX-101 is a fixed-dose combination of D-cycloserine (DCS) and lurasidone, designed to treat acute pyelonephritis. The mechanism of action (MOA) involves the antibacterial properties of DCS, which is a broad-spectrum antibiotic that targets urinary tract pathogens such as E. coli, P. aeruginosa, K. pneumoniae, and A. baumannii. DCS is highly concentrated and unmetabolized in the urine after oral administration, making it effective against these pathogens. Lurasidone, a D2/5-HT2a receptor antagonist, is added to mitigate the potential central nervous system (CNS) effects of DCS. The combination, NRX-101, has been shown to be active against multidrug-resistant strains and has received Qualified Infectious Disease Product (QIDP) and Fast Track designation from the FDA for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis. Currently, the drug is in Phase II stage of its clinical trial.
Further product details are provided in the report……..
Acute Pyelonephritis: Therapeutic Assessment
This segment of the report provides insights about the different Acute Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:
Acute Pyelonephritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Acute Pyelonephritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Pyelonephritis drugs.
Acute Pyelonephritis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Acute Pyelonephritis: Overview
Acute pyelonephritis is a bacterial infection that causes inflammation in the kidney parenchyma and renal pelvis. It typically develops rapidly over a few hours or a day and is often accompanied by high fever, flank pain, nausea, vomiting, and other symptoms. The infection usually ascends from the lower urinary tract but can also spread through the bloodstream. Timely diagnosis and treatment are crucial to prevent serious complications such as kidney scarring, abscess formation, sepsis, and multiorgan system failure. Acute pyelonephritis symptoms typically include fever, flank pain, chills, nausea, vomiting, and anorexia, burning on urination, increased frequency, and urgency. The most common symptoms are fever and flank pain, which can be accompanied by other symptoms such as nausea, vomiting, and abdominal pain that radiates along the flank towards the back. In some cases, symptoms may develop rapidly over a few hours or a day, while in others, they may not occur at the same time. The presentation can vary with age, with newborns often showing poor feeding and vomiting, and children under 2 years old experiencing fever, poor appetite, and vomiting.
It is diagnosed primarily through a combination of clinical evaluation, urinalysis, and laboratory tests. The diagnosis is often suggested by the patient's history and physical examination, which typically includes symptoms such as fever, costovertebral angle pain, nausea, vomiting, and flank pain. Urinalysis is crucial, as it can reveal signs of pyuria, hematuria, or leukocytosis. Laboratory tests, such as blood cultures and peripheral blood smears, may also be ordered to confirm the diagnosis. Imaging studies, such as ultrasound or CT scans, are usually reserved for cases where the presentation is atypical or the patient does not respond to therapy, as they can help identify complications like nephrolithiasis, obstructive uropathy, or perinephric abscess.
Acute pyelonephritis is typically treated with antibiotics, with the choice of antibiotic depending on the identified bacteria. For uncomplicated cases in young, healthy women, a single dose of a parenteral antibiotic followed by oral therapy is effective. For more severe cases or those in high-risk groups (e.g., elderly, pregnant, or immunocompromised), hospitalization with intravenous antibiotics is recommended. Outpatient therapy is also successful in 90% of selected patients with uncomplicated acute pyelonephritis who can tolerate oral intake, are compliant with the treatment regimen, and have adequate social support. The duration of treatment varies, with 14 days being the standard for most cases, but 7 days being sufficient for young, healthy women receiving fluoroquinolones
""Acute Pyelonephritis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pyelonephritis pipeline landscape is provided which includes the disease overview and Acute Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Acute Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve Acute Pyelonephritis.
This segment of the Acute Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Pyelonephritis Emerging Drugs
NRX-101: NeuroRx
NRX-101 is a fixed-dose combination of D-cycloserine (DCS) and lurasidone, designed to treat acute pyelonephritis. The mechanism of action (MOA) involves the antibacterial properties of DCS, which is a broad-spectrum antibiotic that targets urinary tract pathogens such as E. coli, P. aeruginosa, K. pneumoniae, and A. baumannii. DCS is highly concentrated and unmetabolized in the urine after oral administration, making it effective against these pathogens. Lurasidone, a D2/5-HT2a receptor antagonist, is added to mitigate the potential central nervous system (CNS) effects of DCS. The combination, NRX-101, has been shown to be active against multidrug-resistant strains and has received Qualified Infectious Disease Product (QIDP) and Fast Track designation from the FDA for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis. Currently, the drug is in Phase II stage of its clinical trial.
Further product details are provided in the report……..
Acute Pyelonephritis: Therapeutic Assessment
This segment of the report provides insights about the different Acute Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Acute Pyelonephritis
- There are approx. 4+ key companies which are developing the therapies for Acute Pyelonephritis. The companies which have their Acute Pyelonephritis drug candidates in the most advanced stage, i.e. Phase II include, NeuroRx.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Acute Pyelonephritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Acute Pyelonephritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Pyelonephritis drugs.
Acute Pyelonephritis Report Insights
- Acute Pyelonephritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Pyelonephritis drugs?
- How many Acute Pyelonephritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Pyelonephritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Pyelonephritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Pyelonephritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Nabriva Therapeutics
- Wockhardt
- Jiangsu HengRui Medicine
- ZTI-01
- WCK 4282
- HRS -8427
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Acute Pyelonephritis: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Acute Pyelonephritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- NRX-101: NeuroRx
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Acute Pyelonephritis Key Companies
- Acute Pyelonephritis Key Products
- Acute Pyelonephritis- Unmet Needs
- Acute Pyelonephritis- Market Drivers and Barriers
- Acute Pyelonephritis- Future Perspectives and Conclusion
- Acute Pyelonephritis Analyst Views
- Acute Pyelonephritis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
